Comparison of V1-69 CDR3 sequences
| . | SG-MALT4-150 . | CLL4-151 . |
|---|---|---|
| Length | 13.9 ± 1.5 | 19.0 ± 3.5 |
| JH4 | 15/17 (88%) | 1/26 (4%) |
| JH6 | 0/17 | 12/26 (46%) |
| 1st AA-E | 10/17 (59%) | 1/26 (4%) |
| 5′J AA-P | 8/17 (47%) | 0/26 |
| . | SG-MALT4-150 . | CLL4-151 . |
|---|---|---|
| Length | 13.9 ± 1.5 | 19.0 ± 3.5 |
| JH4 | 15/17 (88%) | 1/26 (4%) |
| JH6 | 0/17 | 12/26 (46%) |
| 1st AA-E | 10/17 (59%) | 1/26 (4%) |
| 5′J AA-P | 8/17 (47%) | 0/26 |
SG-MALT = salivary gland mucosa-associated lymphoid tissue; CLL = chronic lymphocytic leukemia.
SG-MALT data from this and previous studies.4 5 1st AA-E refers to the first amino acid at V-D junction being glutamate (E), whereas 5′J AA-P refers to a proline being immediately 5′ to the J segment start (Figure 2).
CLL data from Johnson et al.10